The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.
PPF Group, a Czech Republic-based investment firm, announced on Sept. 16, 2019 that it has acquired a 19.2% stake in Autolus Therapeutics, a London-based biopharmaceutical company specializing in next-generation T cell programming technologies.
Autolus, whose drug development is focused on precisely targeted, controlled, and highly active chimeric antigen receptor (CAR)-T cell products, is developing a pipeline of next-generation T cell therapies targeting both hematological cancers and solid tumors. The company’s lead program, AUTO1, is expected to enter a pivotal Phase II study in patients with adult relapsed or refractory acute B lymphocytic leukemia later in 2019 with an anticipated filing for marketing authorization in 2021.
With investments in both Autolus and a majority-owned biotechnology company, SOTIO, also based in the Czech Republic, PPF aims to become a fully integrated oncology specialty pharma company. With SOTIO, PPF has built a biotechnology portfolio through in-house R&D, investments, acquisitions, and in licensing of products with companies like NBE-Therapeutics, Cellestia Biotech, Cytune Pharma, and Lead Discovery Center. SOTIO is developing a proprietary dendritic cell-based cell therapy platform (DCVAC) and has significant manufacturing and regulatory expertise in the domain of cellular therapies. SOTIO also recently initiated a Phase I/Ib clinical trial with its interleukin-15 superagonist, SO-C101.
“We are very excited by our investment into Autolus. The data published by Autolus on their CAR-T programs is very promising and their long-term ambitions are a perfect match with PPF’s strategy in healthcare,” said Ladislav Bartonicek, shareholder of PPF responsible for the biotechnology sector, in a company press release. “Our investment in Autolus confirms the long-term commitment of PPF and SOTIO to build a strong biotechnology portfolio developing a broad range of its own oncology products and investing in various biotech companies with promising new therapies.”
Source: PPF Group
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 31st 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.